Tabernanthalog

Tabernanthalog (TBG, DLX-007)^[1] is a novel water-soluble, non-toxic ibogalog or simplified analogue of the psychoactive drug tabernanthine first synthesized by David E. Olson at UC Davis.

Tabernanthalog

Clinical data
Other names	TBG; DLX-007; DLX007
Identifiers
IUPAC name 8-methoxy-3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indole
CAS Number	2483829-59-8
PubChem CID	146026994
ChemSpider	114959868
CompTox Dashboard (EPA)	DTXSID301336754
Chemical and physical data
Formula	C14H18N2O
Molar mass	230.311 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1CCC2=C(CC1)NC3=C2C=CC(=C3)OC
InChI InChI=1S/C14H18N2O/c1-16-7-5-12-11-4-3-10(17-2)9-14(11)15-13(12)6-8-16/h3-4,9,15H,5-8H2,1-2H3 Key:FNGNYGCPNKZYOG-UHFFFAOYSA-N

Tabernanthalog is a non-hallucinogenic serotonin 5-HT_2A receptor agonist.^[2] It is also a serotonin 5-HT_2B receptor antagonist.^[2] The drug is described as having high selectivity for the serotonin 5-HT₂ receptors.^[2] Other targets of the drug include monoamine oxidase A (MAO-A), the α_2A-adrenergic receptor, the serotonin 5-HT_1B and 5-HT_2C receptors, and the serotonin transporter (SERT).^[2]

In rodents, it was found to promote structural neural plasticity, reduce drug seeking behavior, and produce antidepressant like effects.^[1][3][4][5] It has also been shown that it effectively reduces motivation for heroin and alcohol in rats. This indicates its efficacy in animals with a history of heroin and alcohol polydrug use.^[5]

Due to the rapidly-induced and enduring neuroplasticity, tabernanthalog is a member of the class of compounds known as non-hallucinogenic psychoplastogens.^[1] This compound, as well as related compounds, are licensed by Delix Therapeutics and are being developed as potential medicines for neuropsychiatric disorders.^[6]

See also

• Ibogalog
• DLX-159
• Ibogaminalog
• PNU-22394
• Psychoplastogen
• Delix Therapeutics
• David E. Olson